GFS Advisors LLC Purchases New Position in Teva Pharmaceutical Industries Ltd. $TEVA

GFS Advisors LLC purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, Holdings Channel reports. The firm purchased 20,000 shares of the company’s stock, valued at approximately $404,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cromwell Holdings LLC increased its holdings in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries in the second quarter worth $41,000. LRI Investments LLC grew its holdings in shares of Teva Pharmaceutical Industries by 246.0% during the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after purchasing an additional 2,000 shares during the last quarter. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at $65,000. Finally, MAI Capital Management raised its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after buying an additional 697 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the sale, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. This represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 422,060 shares of company stock valued at $12,254,965 in the last three months. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Down 1.1%

Shares of NYSE TEVA opened at $33.92 on Friday. The company’s 50 day simple moving average is $31.97 and its 200 day simple moving average is $24.31. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The firm has a market capitalization of $38.90 billion, a P/E ratio of 28.27, a P/E/G ratio of 1.95 and a beta of 0.70. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Jefferies Financial Group increased their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Scotiabank upped their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Finally, Bank of America increased their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.11.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.